Related Experiment Videos
Probucol inhibits lipid peroxidation of macrophage and affects its secretory properties
1Department of Pharmacology, Hengyang Medical College, Hengyang 421001, China.
Aim:
To investigate the mechanisms of anti-atherogenic actions of probucol.
Methods:
Human peripheral blood monocytes were cultured, and treated by copper ion (10 mumol/L) and/or probucol (PBC). Lipid peroxidation was measured by assaying malondialdehyde (MDA). The cytokine interleukin-1 beta (IL-1 beta) and apolipoprotein E (apo E) secreted by monocyte were assayed by enzyme linked immunoassay (ELISA).
Results:
PBC 10-80 mumol/L inhibited copper ion-induced cellular lipid peroxidation from 15.30 to 7.74 mumol MDA/g cell protein. PBC 40 mumol/L inhibited oxidized macrophage-mediated oxidation of LDL from 5.18 to 1.65 mumol MDA/g cell protein, and attenuated secretory properties of monocytes induced by copper ion. The release of apo E, which is involved in reverse cholesterol transport, increased by 65%. And the release of IL-1 beta, which was shown to enhance vascular smooth muscle cell proliferation, decreased by 45%.
Conclusion:
Probucol inhibits lipid peroxidation of macrophages and affects their secretory properties.
Insights
Probucol (PBC) reduces lipid peroxidation in macrophages, a key factor in atherosclerosis. This study shows PBC also modulates monocyte secretion, increasing beneficial apolipoprotein E and decreasing inflammatory interleukin-1 beta.
Area of Science:
- Biochemistry
- Immunology
- Cardiovascular Research
Background:
- Atherosclerosis is a chronic inflammatory disease characterized by lipid accumulation and oxidation in artery walls.
- Macrophage dysfunction, including lipid peroxidation and altered cytokine secretion, plays a critical role in atherogenesis.
- Probucol is a lipid-lowering drug with known antioxidant properties, but its precise anti-atherogenic mechanisms require further elucidation.
Purpose of the Study:
- To investigate the anti-atherogenic mechanisms of probucol (PBC) at the cellular level.
- To determine the effects of probucol on lipid peroxidation and secretory properties of human monocytes.
- To assess probucol's impact on key molecules involved in reverse cholesterol transport and inflammation.
Main Methods:
- Human peripheral blood monocytes were cultured and treated with copper ions and/or probucol.
- Lipid peroxidation was quantified by measuring malondialdehyde (MDA) levels.
- Secretion of apolipoprotein E (apo E) and interleukin-1 beta (IL-1 beta) was measured using enzyme-linked immunoassay (ELISA).
Main Results:
- Probucol significantly inhibited copper ion-induced lipid peroxidation in monocytes.
- Probucol reduced oxidized low-density lipoprotein (LDL) mediated oxidation.
- Probucol treatment increased the secretion of apolipoprotein E by 65% and decreased interleukin-1 beta secretion by 45%.
Conclusions:
- Probucol demonstrates anti-atherogenic effects by inhibiting macrophage lipid peroxidation.
- Probucol modulates monocyte secretory function, enhancing beneficial apo E and reducing pro-inflammatory IL-1 beta.
- These findings highlight probucol's potential therapeutic role in managing atherosclerosis through direct effects on immune cells.